Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29027428 | 1.00 | CA12 (0.38) | CA12CA7CA14SMN1; SMN2PKM | |
| SCHEMBL29926166 | 0.98 | CA12 (0.39) | CA12CA7CA14SMN1; SMN2PKM | |
| SCHEMBL49152 | 0.98 | CA12 (0.39) | CA12CA7CA14SMN1; SMN2PKM | |
| SCHEMBL5492640 | 0.96 | CA12 (0.38) | CA12CA7CA14SMN1; SMN2PKM | |
| Water SCHEMBL730524 | 0.96 | CA12 (0.38) | CA12CA7CA14SMN1; SMN2PKM | |
| Hydrochloric Acid SCHEMBL28285547 | 0.94 | CA12 (0.37) | CA12CA7CA14SMN1; SMN2PKM | |
| SCHEMBL62393 | 0.82 | KDM4E (0.32) | LMNAKDM4EGAA | |
| SCHEMBL15572838 | 0.78 | CA12 (0.41) | CA12CA7CA14SMN1; SMN2PKM | |
| SCHEMBL4694756 | 0.78 | CA12 (0.41) | CA12CA7CA14SMN1; SMN2PKM | |
| Water SCHEMBL28800260 | 0.78 | KDM4E (0.30) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118421751-A | Thrombin aqueous solution and antithrombin III activity detection kit and application thereof in antithrombin III activity detection | 深圳麦科田生物医疗技术股份有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-109836399-A | A kind of synthetic method of biological buffer-morpholinoethanesulfonic acid | 荆楚理工学院 | 2019-06-04 | — | — | CN | claimed |
| CN-118421751-A | Thrombin aqueous solution and antithrombin III activity detection kit and application thereof in antithrombin III activity detection | 深圳麦科田生物医疗技术股份有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-113015523-B | Solid forms of azopyrimidine compounds | 艾库斯生物科学有限公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-4316519-A2 | ANTIBODIES WITH MODULATED GLYCAN PROFILES | AMGEN, INC. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-114304514-B | Mung bean milk rich in GABA and AKG and preparation method thereof | 北京工商大学 | 2023-10-13 | — | — | CN | disclosed |
| CN-116768859-A | Azolopyrimidines for the treatment of cancer related disorders | 艾库斯生物科学有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116669811-A | Compositions and methods for enhancing visual function | 加利福尼亚大学董事会 | 2023-08-29 | — | — | CN | disclosed |
| CN-110214012-B | Azolopyrimidines for the treatment of cancer related disorders | 艾库斯生物科学有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-115998896-A | Fc-III-4C polypeptide-macromolecule-drug conjugate, and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2023-04-25 | — | — | CN | disclosed |
| EP-3788076-A1 | ANTIBODIES WITH MODULATED GLYCAN PROFILES | Amgen Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20210062156-A1 | ANTIBODIES WITH MODULATED GLYCAN PROFILES | AMGEN INC. (US) | 2021-03-04 | — | — | US | disclosed |
| CN-109836399-A | A kind of synthetic method of biological buffer-morpholinoethanesulfonic acid | 荆楚理工学院 | 2019-06-04 | — | — | CN | disclosed |
| US-7563824-B2 | Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals | Italian Joint Stock Company (IT) | 2009-07-21 | — | — | US | disclosed |
| US-7060170-B2 | Bridges, elements and junctions for electroosmotic flow systems | EKSIGENT TECHNOLOGIES LLC (US) | 2006-06-13 | — | — | US | disclosed |
| US-20040076680-A1 | Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals | SLOVAK ACADEMY OF SCIENCES (SK) | 2004-04-22 | — | — | US | disclosed |
| US-20030206806-A1 | Bridges, elements and junctions for electroosmotic flow systems | AB SCIEX LLC | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210062156-A1 | ANTIBODIES WITH MODULATED GLYCAN PROFILES | FCGR1A, FCGR2A, FCGR3B | CA12 272/4885CA7 1454/4885CA14 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.